Log in to your Inderes Free account to see all free content on this page.
CellaVision
156.20 SEK
+2.76 %
1,475 following
CEVI
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for CellaVision
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 461.8 | 471.4 | 565.6 | 639.3 | 677.3 | 723.2 | 759.0 |
| growth-% | 2.1 % | 20.0 % | 13.0 % | 5.9 % | 6.8 % | 4.9 % | |
| EBITDA | 146.7 | 142.9 | 196.2 | 198.0 | 207.0 | 219.0 | 241.4 |
| EBIT | 126.6 | 110.3 | 162.7 | 158.3 | 167.1 | 177.7 | 202.1 |
| Profit before taxes | 129.2 | 112.2 | 158.3 | 148.4 | 164.2 | 176.9 | 194.3 |
| Net income | 99.2 | 89.5 | 125.3 | 118.3 | 130.3 | 140.7 | 153.1 |
| EPS | 4.16 | 3.75 | 5.25 | 4.96 | 5.46 | 5.90 | 6.42 |
| Dividend | 0.00 | 0.75 | 2.00 | 2.00 | 2.25 | 2.50 | 2.75 |
| Dividend ratio | 0.0 % | 20.0 % | 38.1 % | 40.3 % | 41.2 % | 42.4 % | 42.8 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 31.8 % | 30.3 % | 34.7 % | 31.0 % | 30.6 % | 30.3 % | 31.8 % |
| EBIT-% | 27.4 % | 23.4 % | 28.8 % | 24.8 % | 24.7 % | 24.6 % | 26.6 % |
| ROE | 28.5 % | 20.8 % | 23.1 % | 18.4 % | 18.2 % | 17.3 % | 17.2 % |
| ROI | 15.5 % | 13.4 % | 15.2 % | 13.3 % | 14.0 % | 13.9 % | 14.0 % |
Login required
This content is only available for logged in users